论文部分内容阅读
目的:观察~(131)I治疗Graves甲亢的临床疗效及安全性。方法:选取2013年1月至2013年12月于我院就诊的120例Graves甲亢患者作为观察对象,所有患者均接受~(131)I治疗,观察甲亢临床疗效、甲亢复发率、不良反应及并发症发生情况。结果:甲亢临床疗效显示,~(131)I组患者治愈率及总有效率分别为80.8%和95.8%。随访2年,复发率为4.2%。无甲亢性心脏病、肝功能损伤发生,其中甲减发生率为18.3%。结论:尽管有较高的甲减发生率,~(131)I治疗Graves甲亢疗效高,复发率低,甲亢性心脏病、肝功能损伤等不良反应及并发症发生率低,安全性好,临床上值得应用。
Objective: To observe the clinical efficacy and safety of ~ (131) I in treating Graves’ hyperthyroidism. Methods: One hundred and twenty patients with Graves hyperthyroidism who were treated in our hospital from January 2013 to December 2013 were enrolled in this study. All patients received ~ (131) I treatment. The clinical efficacy, the recurrence rate of hyperthyroidism, adverse reactions and complications Occurrence of disease. Results: The clinical effect of hyperthyroidism showed that the cure rate and total effective rate of ~ (131) I group were 80.8% and 95.8% respectively. Followed up for 2 years, the recurrence rate was 4.2%. No hyperthyroidism heart disease, liver damage occurred, including hypothyroidism rate of 18.3%. CONCLUSIONS: Despite the high incidence of hypothyroidism, 131I treatment of Graves hyperthyroidism has high efficacy, low recurrence rate, adverse reactions such as hyperthyroid heart disease, liver dysfunction and low incidence of complications, safety, and clinical It is worth applying.